IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
- 07 November 2023 - 1 mins read
| Statement of transactions in own shares from October 30 to November 03, 2023
|
BNP PARIBAS | ||||||||||
|
|
|||||||||||
| Aggregated presentation by day and by market | |||||||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 22 | 111.80 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 240 | 111.70 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 41 | 111.90 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 30/10/2023 | FR0010259150 | 1,908 | 111.83 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 41 | 112.10 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 161 | 112.80 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 226 | 112.70 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 31/10/2023 | FR0010259150 | 2,572 | 112.95 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 182 | 112.72 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 286 | 112.96 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 47 | 112.94 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 01/11/2023 | FR0010259150 | 2,485 | 112.84 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 289 | 112.09 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 165 | 112.57 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 92 | 112.05 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 02/11/2023 | FR0010259150 | 2,454 | 112.68 | XPAR | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 162 | 110.80 | AQEU | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 94 | 110.93 | CEUX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 4 | 110.70 | TQEX | |||||
| IPSEN | 549300M6SGDPB4Z94P11 | 03/11/2023 | FR0010259150 | 2,740 | 111.09 | XPAR | |||||
| * Two-digit rounding after the decimal | TOTAL | 14,211 | 112.27 | ||||||||
Attachment
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read
Testing video 2
13 August 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024
06 August 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2024
05 August 2024
1 mins read